Tarsus Pharmaceuticals, Inc. TARS Depreciation
Depreciation at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s depreciation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s depreciation?
- Tarsus Pharmaceuticals, Inc. (TARS) reported depreciation of $197K in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s depreciation changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s depreciation decreased by 10.5% year-over-year, from $220K to $197K.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s depreciation?
- Over 2 years (2023 to 2025), Tarsus Pharmaceuticals, Inc.'s depreciation has grown at a 4.6% compound annual growth rate (CAGR), from $751K to $822K.